CVS HEALTH Corp (CVS): what the price assumes

boothcheck covers CVS HEALTH Corp (CVS) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/CVS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6% sits below it).

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.0%); the inversion above states its own rate.

Per-Model Detail (n=12)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 5.8%); the trailing year was depressed.

Bullet Takeaways

• Retail prescription volume keeps rising while the drug-benefit arm loses ground: prescriptions filled reached 1,808.8 million on a 30-day equivalent basis in 2025, up 5.4%, while pharmacy claims processed fell 0.9% on the same basis.

• Reported operating income dropped to $4,660 million in 2025 from $8,516 million a year earlier, a fall the filing attributes "primarily due to a $5.7 billion goodwill impairment charge" against the health insurance business, which is why every backward-looking measure of this company currently reads badly.

• Second quarter results land on August 5, 2026, and the quarterly dividend was declared at $0.665 a share on July 10.

Bull Case

Set the standard yardsticks against a $107.73 share and the picture is uniformly unflattering. The asset lens sits below the price. So does the earnings-power lens, by a wide margin, and so does the peer-multiple comparison. Only the forward cash-flow approach lands anywhere near it. That should be the end of the argument, and it is not, because of what those yardsticks are reading. Every one of them measures a period in which reported operating income fell to $4,660 million from $8,516 million the year before and $13,743 million the year before that, and the filing says the drop came "primarily due to a $5.7 billion goodwill impairment charge". Writing down goodwill is an accounting statement that a past acquisition cost more than it was worth. It takes nothing out of this year's cash and nothing out of next year's.

Underneath the accounting, volume moved the other way. Prescriptions filled reached 1,808.8 million on a 30-day equivalent basis in 2025, up 5.4% after 4.0% the year before, dispensed across roughly 9,000 retail locations. The benefits arm covered an estimated more than 37 million people at the end of December. Neither of those is a business losing customers. They are businesses earning less per customer, which is a different problem with a different remedy.

The structural argument is about where profit can be moved rather than where it currently sits. The retail arm "provides pharmacy fulfillment services to support the Health Services segment's specialty and mail order pharmacy offerings", and the insurance arm buys drug management from the same house. When a regulator or a client squeezes one link, an owner of the whole chain has somewhere to put the pressure. That optionality never appears in any individual segment's margin, which is exactly why reading this company one segment at a time understates what the combination can do.

Thin margins deserve their industry context before they are treated as a verdict. HUM runs a 1.8% operating margin on $137.2 billion of revenue, MCK 1.5% on $403.4 billion, CAH 1.0% on $244.7 billion, and COR 0.85% on $328.7 billion. Moving medicine at national scale is a business of pennies on large numbers, and it always has been. The relevant question is not whether the margin is small but whether it is smaller than it should be, and 2025 answered that with a one-time charge rather than with a structural one.

Cash arrived regardless of what the goodwill line said. Free cash flow ran $7.394 billion over the trailing year, the dividend has continued, and the share count has drifted down about 0.9% a year across four years. A company that writes off five point seven billion of an old purchase price and still generates that much cash in the same twelve months is telling the reader something about the difference between accounting profit and the money the business actually throws off.

Bear Case

The clearest evidence of competitive pressure is in the company's own volume disclosure, and it points the wrong way. Pharmacy claims processed fell 0.9% on a 30-day equivalent basis in 2025 while retail scripts grew. The 10-K explains the mechanism without varnish: "PBM clients are generally well informed, can move between us and our competitors and often seek competing bids prior to expiration of their contracts", in an industry that "has been experiencing price compression as a result of competitive pressures and increased client demands for lower prices". The two rivals that matter most are not independent firms that can be outlasted. They sit inside UNH and CI, which earn 4.2% and 3.4% operating margins on $449.7 billion and $277.9 billion of revenue respectively, against about 1.8% here on a trailing basis. When three vertically integrated giants compete on price, the winner is whoever can live on the thinnest spread, and on current figures that is not this one.

Retail faces a different kind of attacker. WMT's own filing names among its risks "competitors offering online retail pharmacy options and/or home delivery options" and "further consolidation and strategic alliances among third-party payers, PBMs or purchasers of drugs". WMT earns a 4.2% operating margin on $725.3 billion of revenue and COST 3.8% on $293.6 billion, both while dispensing the same medicines. A competitor whose margin is earned somewhere other than the pharmacy counter can price that counter with a freedom this company does not have.

The regulator is the third front, and it is now on the record. CVS Caremark finalized a settlement with the Federal Trade Commission on July 14, 2026 covering its approach to transparency and affordability. The 10-K had already listed the exposures in detail: pricing spread between what a plan sponsor is charged and what the dispensing pharmacy is paid, rebate sharing, guarantee reconciliation, disclosure of data. Each of those is a place where a rule change removes revenue that costs nothing to remove.

The financial position leaves less room than the revenue line suggests. Borrowings less liquid assets come to roughly 54 billion dollars on the funded-debt measure and roughly 76 billion once lease obligations are counted alongside them. Interest expense has risen in each of the last three years, to $3,119 million in 2025 from $2,958 million and $2,658 million before it, while operating income moved the opposite way over the same span. In 2023 the operating line was $13,743 million against $2,658 million of interest. In 2025 it was $4,660 million against $3,119 million. The cushion between what the business earns and what it owes the lenders has largely gone, and it went in three years.

The goodwill charge deserves a second reading from this side. A five point seven billion dollar impairment against the health insurance business is management's own written statement that the price paid for that business will not be recovered. The bull is right that the entry moved no cash and constrains no future year. Both readings hold at once. It is a non-cash accounting entry, and it is an admission, and the segment it was taken against is the one now competing hardest on price.

Valuation

Buy the shares at $107.73 and the equity is a claim on a business the market values at about 213.5 billion dollars once borrowings are added alongside the 137.8 billion of stock. More than a third of the enterprise belongs to lenders before a shareholder sees anything. That is the single most important fact about how this security behaves, and it explains most of what follows.

A capital structure of that shape turns a modest change in operating profit into a large change in what reaches the equity. Which is why the backward-looking measures, all of them reading a year carrying a five point seven billion dollar write-off, land so far under the price, while the forward cash-flow approach lands close to it. The peer-multiple comparison is the least distorted of the group and worth quoting for that reason: on enterprise value against EBITDA the sector reference sits near fourteen, and applied to the 10.53 billion of EBITDA this business produced, the price stands roughly 70% above where that peer-multiple reading lands.

The cleanest earnings reference available is the five-year average operating profit with one-time charges added back, which comes to about 11.12 billion dollars. Capitalizing that with no growth assumed at all still leaves a figure well beneath today's quote. Stated without the arithmetic: the price requires the operating line to recover, not merely to stop falling. That line went $13,743 million, then $8,516 million, then $4,660 million across 2023, 2024 and 2025. Two thirds of it disappeared in two years, and the price is paid on the assumption that a good part of it comes back.

Cohort position is the more reassuring half of the picture, and it is worth being precise about. Measured against the multiple range its peers occupy, this name sits in the lower half rather than the top. UNH earns a 4.2% operating margin on $449.7 billion of revenue growing 9.7%; CI earns 3.4% on $277.9 billion growing 8.8%; ELV earns 3.1% on $200.4 billion growing 9.3%. This company earns about 1.8% on a trailing basis on $407.9 billion. Nobody is paying a premium multiple here. They are paying an unremarkable one for a company whose reported profit has fallen by two thirds, and the entire question is which of those two facts is the more durable.

Solvency is the constraint to watch rather than the danger to fear. Liquid assets of 11.802 billion dollars sit against borrowings of 65.896 billion, leaving net obligations near 54 billion on the funded-debt build and near 76 billion once leases are included alongside them. Free cash flow of $7.394 billion over the trailing year services the $3,119 million interest bill and the dividend with room to spare, so the position is workable at today's depressed earnings rather than dependent on the recovery. What the price is arguing about is therefore neither the balance sheet nor the multiple. It is whether $4,660 million was the floor of the operating line or a waypoint on the way down.

Catalysts

Second quarter results are due on August 5, 2026. Two lines carry more information than the headline. The first is the medical benefit ratio in the insurance segment, which the filing defines as health care costs divided by premium revenue and which is the direct measure of whether the pricing taken on this year's Medicare and commercial books was adequate. The second is pharmacy claims processed, the volume figure that fell 0.9% on a 30-day equivalent basis last year. One tells you whether the insurance business is repaired. The other tells you whether the drug-benefit business is still shedding clients.

The regulatory picture moved in July. CVS Caremark finalized a settlement with the Federal Trade Commission on July 14, 2026 addressing its approaches to transparency and affordability. Settlements of this kind close a specific exposure and leave the underlying commercial question open, since the pricing practices at issue are the same ones the 10-K lists as competitive battlegrounds. On the sell side, UBS raised its target to $122 from $115 on July 23 while keeping a buy rating. That figure sits above the current quote and reflects a view on the earnings recovery rather than on the trailing numbers, which are what the measures used above describe.

Two smaller items are worth noting because they show where management is spending attention. The quarterly dividend was declared at $0.665 a share on July 10, which is a continuation rather than a change and a signal that the payout is not currently under review. And on July 21 the company began dispensing common pet medications through its roughly 9,000 locations. That will not move a company with revenue near $407.9 billion by itself. It is worth watching as an example of the strategy in the retail arm, which is to defend the traffic that pays for the store base by widening what the store base can dispense.

Peer Cohorts (Per Segment, With Filing Citations)

Health Care Benefits (reported)

• UNH (UnitedHealth Group Incorporated)
• FY2025 10-K: …operations in an effort to mitigate these impacts. In addition, if these providers refuse to contract with us, use their market position to negotiate favorable contracts or place us at a competitive disadvantage, our ability to market products or to be profitable in those areas could be materially and adversely…
• FY2025 10-K: …provides employer-sponsored health benefits, as well as individual and family plans through portfolio of products which include consumer engagement products, such as high-deductible consumer driven benefit plans and a variety of innovative consumer centric products; traditional products; clinical and pharmacy…
• ELV (ELEVANCE HEALTH, INC.)
• FY2025 10-K: …with our customers, care providers, brokers, agents, employees and other stakeholders through technological solutions and operational improvements, including advanced tools that support distribution, service, clinical coordination and administrative efficiency. Through our participation in various federal government…
• FY2025 10-K: …of operations for our Health Benefits segment include membership levels and the health status of our members, premium pricing, medical cost trend, network performance, risk adjustment accuracy, quality ratings, and operating efficiency. This segment benefits from working with our Carelon businesses, which support…
• HUM (HUMANA INC)
• FY2025 10-K: Total premiums revenue 122,825 95.5 % Services: Military services and other 1,017 0.8 % Services revenue 1,017 0.8 % Total Insurance segment premiums and services revenue $ 123,842 96.3 % Medicare We have participated in the Medicare program for private health plans for over 30 years and have established a national…
• FY2025 10-K: • Long-term care insurance • Weekly paid well-being time • Whole-person well-being and rewards programs and platform • On-demand fitness classes, nutritional education through teaching kitchens, and digital coaching apps • Incentives for engaging in well-being programs Life • Paid time off, paid holidays, paid…
• CI (The Cigna Group)
• FY2025 10-K: …partnerships with high-performing providers and superior clinical expertise and analytics to guide customers to the highest quality, most affordable sites of care and reduce health care waste. • Talented and experienced people who bring a highly consultative orientation to market and partner with clients to…
• FY2025 10-K: …give the Company the right to adjust reimbursement rates during the annual guarantee period. E. Premiums and Related Expenses Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses…
• CNC (CENTENE CORPORATION)
• FY2025 10-K: …may result in an additional monthly premium charged to the enrollee or through portions of payments received from CMS that may be allocated to these benefits, according to CMS regulations and guidance. Typically, as our Medicare Advantage members reach their deductibles and out-of-pocket maximums, our medical costs…
• FY2025 10-K: …guidance and other rulemaking changes will be critical to ensuring state and MCO implementation readiness. Medicare Medicare is the federal health insurance program for people ages 65 and over, which was expanded to cover people under 65 with certain disabilities and people with end-stage renal disease requiring…
• MOH (MOLINA HEALTHCARE, INC.)
• FY2025 10-K: The vast majority of Marketplace membership is comprised of low-income members who receive government subsidies, which is served by a limited number of health plans. Our primary competitor for low-income Marketplace membership is Centene Corporation. We compete for agents and brokers to recommend and distribute our…
• FY2025 10-K: …Although most of our health plans over the last several years have generally operated with profit margins higher than those of our direct competitors, nevertheless the profit margins of our health plans are low (in the single digits) compared to the profit margins in most other industries or business sectors. Given…
• OSCR (Oscar Health, Inc.)
• FY2025 10-K: …and results of operations, including pricing, minimum MLRs, administration of the risk adjustment program, and the geographies in which our products are available. The ACA prohibits annual and lifetime limits on essential health benefits, member cost-sharing on specified preventive benefits, and pre-existing…
• FY2025 10-K: …in material respects from our core health insurance operations and subjects us to additional operational, regulatory, and financial risks. For example, the agency generates a substantial portion of its revenue from commissions and other compensation paid by health insurance carriers, including us and third-party…
• ALHC (ALIGNMENT HEALTHCARE, INC.)
• FY2025 10-K: …Advantage plans, changes to provisions for risk sharing under Medicare Part D and risks related to governmental audits and investigations, among others. A significant portion of our revenue relates, directly or indirectly, to the Medicare Advantage program, which accounted for substantially all of our total revenue…
• FY2025 10-K: …and cost effective. Competition The U.S. healthcare insurance industry is highly competitive. Our competitors vary by local market and include other managed care companies, national insurance companies, HMOs and PPOs. Many of our competitors have a larger membership base and/or greater financial resources than we do.…

Health Services (reported)

• CI (The Cigna Group)
• FY2025 10-K: …partnerships with high-performing providers and superior clinical expertise and analytics to guide customers to the highest quality, most affordable sites of care and reduce health care waste. • Talented and experienced people who bring a highly consultative orientation to market and partner with clients to…
• FY2025 10-K: …11%, or $5,751 million, primarily due to the impact of the HCSC transaction (-$8,498 million), partially offset by higher premiums within employer insured (+$1,276 million) and stop loss (+$855 million), primarily reflecting premium rate increases. Pre-tax adjusted income from operations decreased 2%, or $76 million,…
• UNH (UnitedHealth Group Incorporated)
• FY2025 10-K: …public sector employers, mid-sized employers, small businesses, and individuals. As of December 31, 2025, UnitedHealthcare Employer & Individual provides access to medical services for 29.7 million people. UnitedHealthcare Employer & Individual offers risk-based products under which it assumes responsibility for…
• FY2025 10-K: …Provides health care coverage for seniors and other eligible Medicare beneficiaries through the Medicare Advantage program administered by the Centers for Medicare & Medicaid Services (CMS), including Medicare Advantage HMO plans, Preferred Provider Organization (PPO) plans, Point-of-Service plans,…
• MCK (McKESSON CORPORATION)
• FY2025 10-K: …practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services. Our RxTS segment helps solve medication access, affordability and adherence challenges for patients by…
• FY2025 10-K: …policy may also have significant impacts on our business. For example, many pharmaceutical manufacturers have unilaterally restricted sales under the Public Health Service's 340B Drug Pricing Program (the "340B program") to contract pharmacies. The 340B program requires manufacturers to offer discounts on certain…
• COR (CENCORA, INC.)
• FY2025 10-K: …providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers…
• FY2025 10-K: …care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who…
• CAH (Cardinal Health, Inc.)
• FY2025 10-K: …pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of…
• FY2025 10-K: …for the acquisitions came from an $800 million term loan. Cardinal Health | Fiscal 2025 Form 10-K 5 MD&A Overview Significant Developments in Fiscal 2025 and Trends Acquisitions Advanced Diabetes Supply Group ("ADS") On April 1, 2025, we completed the acquisition of ADS, a diabetic medical supplies provider to…
• OPCH (OPTION CARE HEALTH, INC.)
• FY2025 10-K: …and local levels places it in a strong position against existing and potential competitors. Intellectual Property Option Care Health and its subsidiaries own a variety of trademarks, licenses, and service marks, including but not limited to: "Option Care Health", "Option Care", "Critical Care Systems", "Clinical…
• FY2025 10-K: , "our", or the "Company") is the largest independent provider of home and alternate site infusion services through its national network of 196 locations in 43 states. Option Care Health draws on over 40 years of clinical care experience to offer patient-centered, cost-effective infusion therapy. Option Care Health's…

Pharmacy & Consumer Wellness (reported)

• KR (KROGER CO)
• FY2025 10-K: …February 3, 2024. ​ Disaggregated Revenues ​ The following table presents sales revenue by type of product for the years ended February 1, 2025, February 3, 2024, and January 28, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2024 ​ 2023 (3) ​ 2022 (3) ​ Amount % of total Amount % of total Amount % of total Non…
• FY2025 10-K: ; ​ ​ ​ 2024 ​ 2023 ​ Gross carrying Accumulated Gross carrying Accumulated ​ ​ amount ​ amortization (1) ​ amount ​ amortization (1) Definite-lived pharmacy prescription files (2) ​ $ 247 ​ $ ( 183 ) ​ $ 360 ​ $ ( 259 ) ​ Definite-lived customer relationships (2) ​ ​ 148 ​ ​ ( 145 ) ​ ​ 186 ​ ​ ( 179 ) ​…
• COST (COSTCO WHOLESALE CORP /NEW)
• FY2025 10-K: …to our business and profitability. This format is designed to reinforce member loyalty and provide continuing fee revenue. The extent to which we achieve growth in our membership base, increase the penetration of Executive memberships, and sustain high renewal rates materially influences our profitability. Our…
• FY2025 10-K: …with us, attracting members of other wholesale club operators, our lesser familiarity with local member preferences, and seasonal differences in the market. Entry into new markets may bring us into competition with new competitors or with existing competitors with a large, established market presence. We cannot…
• WMT (WALMART INC.)
• FY2025 10-K: …pharmacy operations including competitors offering online retail pharmacy options and/or home delivery options; further consolidation and strategic alliances among third-party payers, PBMs or purchasers of drugs; overall economic conditions and the ability of our pharmacy customers to pay for drugs prescribed for…
• FY2025 10-K: …services we offer in areas such as digital advertising, marketplace and fulfillment services, health and wellness, and financial services to provide our customers a broader set of offerings to meet expanding needs. Seasonal Aspects of Operations. Our business is seasonal to a certain extent and varies by country due…
• BJ (BJ’S WHOLESALE CLUB HOLDINGS, INC.)
• FY2025 10-K: …groceries, we accept all manufacturer coupons and also carry our own exclusive brands that enable members to save on price without compromising on quality. Our two private label brands, Wellsley Farms ® and Berkley Jensen ® , represent approximately 26% of our total net sales, excluding gasoline. Our customers…
• FY2025 10-K: …• risks relating to our ability to implement our growth strategy by opening new clubs, and gasoline stations; and 3 • the other risk factors identified in our filings with the Securities and Exchange Commission, including those set forth under "Item 1A. Risk Factors" and "Item 7. Management's Discussion and Analysis…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.